202 related articles for article (PubMed ID: 23724103)
21. The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8.
Banerjee S; Lu J; Cai Q; Saha A; Jha HC; Dzeng RK; Robertson ES
PLoS Pathog; 2013; 9(5):e1003314. PubMed ID: 23658517
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection.
Mrozek-Gorska P; Buschle A; Pich D; Schwarzmayr T; Fechtner R; Scialdone A; Hammerschmidt W
Proc Natl Acad Sci U S A; 2019 Aug; 116(32):16046-16055. PubMed ID: 31341086
[TBL] [Abstract][Full Text] [Related]
23. Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes.
Xu D; Zhao L; Del Valle L; Miklossy J; Zhang L
J Virol; 2008 Jul; 82(13):6251-8. PubMed ID: 18417578
[TBL] [Abstract][Full Text] [Related]
24. Restricted TET2 Expression in Germinal Center Type B Cells Promotes Stringent Epstein-Barr Virus Latency.
Wille CK; Li Y; Rui L; Johannsen EC; Kenney SC
J Virol; 2017 Mar; 91(5):. PubMed ID: 28003489
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas.
Vrzalikova K; Vockerodt M; Leonard S; Bell A; Wei W; Schrader A; Wright KL; Kube D; Rowe M; Woodman CB; Murray PG
Blood; 2011 Jun; 117(22):5907-17. PubMed ID: 21411757
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
Longnecker R
Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
[TBL] [Abstract][Full Text] [Related]
27. Kinetics of interleukin-4 induction and interferon-gamma inhibition of IgE secretion by Epstein-Barr virus-infected human peripheral blood B cells.
Thyphronitis G; Banchereau J; Heusser C; Tsokos GC; Levine AD; Finkelman FD
Cell Immunol; 1991 Apr; 133(2):408-19. PubMed ID: 1849800
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression.
Wang L; Toomey NL; Diaz LA; Walker G; Ramos JC; Barber GN; Ning S
J Virol; 2011 Aug; 85(16):8328-37. PubMed ID: 21680528
[TBL] [Abstract][Full Text] [Related]
29. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
Tanner JE; Alfieri C
Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
[TBL] [Abstract][Full Text] [Related]
30. CD40 ligation downregulates EBNA-2 and LMP-1 expression in EBV-transformed lymphoblastoid cell lines.
Pokrovskaja K; Ehlin-Henriksson B; Kiss C; Challa A; Gordon J; Gogolak P; Klein G; Szekely L
Int J Cancer; 2002 Jun; 99(5):705-12. PubMed ID: 12115504
[TBL] [Abstract][Full Text] [Related]
31. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
Price AM; Messinger JE; Luftig MA
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
[TBL] [Abstract][Full Text] [Related]
32. Multiple Viral microRNAs Regulate Interferon Release and Signaling Early during Infection with Epstein-Barr Virus.
Bouvet M; Voigt S; Tagawa T; Albanese M; Chen YA; Chen Y; Fachko DN; Pich D; Göbel C; Skalsky RL; Hammerschmidt W
mBio; 2021 Mar; 12(2):. PubMed ID: 33785626
[TBL] [Abstract][Full Text] [Related]
33. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
[TBL] [Abstract][Full Text] [Related]
34. Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.
Wilson AD; Morgan AJ
J Virol; 2002 May; 76(10):5071-81. PubMed ID: 11967323
[TBL] [Abstract][Full Text] [Related]
35. K1 and K15 of Kaposi's Sarcoma-Associated Herpesvirus Are Partial Functional Homologues of Latent Membrane Protein 2A of Epstein-Barr Virus.
Steinbrück L; Gustems M; Medele S; Schulz TF; Lutter D; Hammerschmidt W
J Virol; 2015 Jul; 89(14):7248-61. PubMed ID: 25948739
[TBL] [Abstract][Full Text] [Related]
36. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells.
Cahir-McFarland ED; Carter K; Rosenwald A; Giltnane JM; Henrickson SE; Staudt LM; Kieff E
J Virol; 2004 Apr; 78(8):4108-19. PubMed ID: 15047827
[TBL] [Abstract][Full Text] [Related]
37. Dithiocarbamates and viral IL-10 collaborate in the immortalization and evasion of immune response in EBV-infected human B lymphocytes.
Irons RD; Le AT
Chem Biol Interact; 2008 Mar; 172(1):81-92. PubMed ID: 18163983
[TBL] [Abstract][Full Text] [Related]
38. LTRs activated by Epstein-Barr virus-induced transformation of B cells alter the transcriptome.
Leung A; Trac C; Kato H; Costello KR; Chen Z; Natarajan R; Schones DE
Genome Res; 2018 Dec; 28(12):1791-1798. PubMed ID: 30381291
[TBL] [Abstract][Full Text] [Related]
39. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
Kis LL; Takahara M; Nagy N; Klein G; Klein E
Immunol Lett; 2006 Apr; 104(1-2):83-8. PubMed ID: 16386314
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of cell growth and Epstein-Barr virus reactivation by CD40 stimulation in Epstein-Barr virus-transformed B cells.
Fukuda M; Satoh TA; Takanashi M; Hirai K; Ohnishi E; Sairenji T
Viral Immunol; 2000; 13(2):215-29. PubMed ID: 10893001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
